Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 10.4% on 5/9/24. The shares closed at $5.56. Moreover, this advance was accompanied by above average trading volume at 142% of normal. Relative to the market the stock has been weak over the last nine months but has risen 1.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Editas Medicine has a poor Appreciation Score of 22 and a poor Power Rating of 15, and the Lowest Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment